690265-87-3

Usage

Uses

Used in Pharmaceutical Development:
(R)-1-(5-bromo-pyridin-2-yl)-pyrrolidin-3-ol is utilized as a key intermediate in the synthesis of pharmaceuticals, particularly for drugs targeting various diseases. Its unique structural features allow it to interact with biological targets, potentially leading to the development of novel therapeutic agents.
Used in Medicinal Chemistry Research:
As a research tool, (R)-1-(5-bromo-pyridin-2-yl)-pyrrolidin-3-ol aids scientists in understanding the structure-activity relationships of drug candidates. It is employed in the design and optimization of new compounds with improved pharmacological profiles, enhancing the discovery of effective treatments.
Used in Drug Discovery:
(R)-1-(5-bromo-pyridin-2-yl)-pyrrolidin-3-ol is used as a starting material in drug discovery processes, where its chemical properties can be further modified to create new drug candidates. Its potential for various pharmacological activities makes it a valuable component in the development of innovative therapeutics.
Used in Chemical Synthesis:
In the chemical synthesis industry, (R)-1-(5-bromo-pyridin-2-yl)-pyrrolidin-3-ol serves as a versatile building block for the creation of complex organic molecules. Its reactivity and structural attributes enable the synthesis of a wide range of compounds with diverse applications in various fields.

Upstream product

• 766-11-0 5-bromo-2-fluoropyridine 
• 40499-83-0 (3R)-pyrrolidinol 
• 882037-27-6 (R)-2-hydroxypyrrolidine 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 1224170-97-1 (R)-2-(4-chlorophenyl)-5-(6-(3-hydroxypyrrolidin-1-yl)pyridin-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 
• 946001-87-2 (S)-5-bromo-2-[3-(2,6-dichloro-4-methyl-phenoxy)-pyrrolidin-1-yl]-pyridine 

Relevant academic research and scientific papers

Piperidine-based renin inhibitors: Upper chain optimization

The optimization of the 4-position of recently described new 3,4-disubstituted piperidine-based renin inhibitors is reported herein. The synthesis and characterization of compounds leading to the discovery of 11 (ACT-178882, MK-1597), a renin inhibitor wi

AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula (I) including all pharmaceutically acceptable salts and stereoisomers thereof: wherein A is a mo

Primary Amines as Renin Inhibitors

The invention relates to novel primary amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

Secondary Amines as Renin Inhibitors

The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

SECONDARY AMINES AS RENIN INHIBITORS

The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), wherein the groups and radicals A, B, W, X, Y, Z, R1, and R2 have the meanings indicated in claim 1. The invention further relates to medicaments containing at least one inventive alkyne. The disclosed medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, particularly adiposity and diabetes, as a result of the MCH receptor antagonistic activity thereof.

2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R5, Het, X and Cyc are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.